L’immunothérapie dans le cancer de l’ovaire (notice n° 271738)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01819cam a2200313 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112080927.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Le Saux, Olivia |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | L’immunothérapie dans le cancer de l’ovaire |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2019.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 12 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | RésuméIl existe un rationnel biologique fort pour le développement de l’immunothérapie dans le cancer ovarien. Cependant, son efficacité semble limitée en monothérapie chez des patientes lourdement prétraitées. Actuellement, plusieurs études sont en cours, en combinaison aux inhibiteurs de PARP, aux anti-angiogéniques et à la chimiothérapie, pour lesquelles l’identification de biomarqueurs est essentielle. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | There is a strong biological rationale for the development of immunotherapy for ovarian cancer. However, effectiveness appears to be limited as monotherapy in heavily pre-treated patients. Several studies are currently ongoing assessing immune checkpoint blockade with PARP inhibitors, anti-angiogenic therapies, chemotherapy, etc., for which the identification of predictive biomarkers of efficacy is essential. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thérapeutique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | tumeurs de l’ovaire |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunotherapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ovarian tumours |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | therapeutic |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dubois, Bertrand |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Stern, Marc-Henri |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Terme, Magali |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tartour, Eric |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Caux, Christophe |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ray-Coquard, Isabelle |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 5 | 2 | 2019-03-01 | p. 89-92 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2019-2-page-89?lang=fr">https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2019-2-page-89?lang=fr</a> |
Pas d'exemplaire disponible.
Réseaux sociaux